Nativis Adds New Board Member

SEATTLE--(BUSINESS WIRE)--Nativis, Inc. announced today that Chris Rivera, president of the Washington Biotechnology and Biomedical Association (WBBA), founder and former CEO of Hyperion Therapeutics, was appointed to the company’s board of directors.

“Nativis has the potential to dramatically impact how cancer patients are treated around the world, and I am excited to support their efforts to help bring their technology to market and help thousands of patients in a new and unique way.”

“Chris has extraordinary biotechnology industry and business expertise, and we are delighted that he is joining Nativis’s board of directors,” said John Butters, Nativis’s chairman.

Rivera has held a series of senior management posts with top biotech companies, spread around the country, including Cambridge, MA-based Genzyme, South San Francisco-based Tercica, Frazer, PA-based Cephalon, and Horsham, PA-based Centocor. He was most recently the president and CEO of San Francisco-based Hyperion Therapeutics. He holds a master’s degree from the University of Oklahoma Health Sciences Center; a bachelor degree from Northwestern Oklahoma State University; and studied marketing and management at the Albers Graduate School of Business and Economics at Seattle University.

In addition, Mr. Rivera has been appointed to several leadership positions, including the Governor’s Higher Education Task Force and the Washington Global Health Funding Commission. He is currently the Chairman for the national Council of State Bioscience Associations.

“I am honored to join the Nativis board and work with this exceptional team,” Rivera said. “Nativis has the potential to dramatically impact how cancer patients are treated around the world, and I am excited to support their efforts to help bring their technology to market and help thousands of patients in a new and unique way.”

Founded in 2002, Nativis is a Seattle based life sciences company developing low-level radio frequency energy (RFE) products to treat cancer and other serious diseases.

Note to editors: For more information, please send an email request to corporate@nativis.com.